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Monoamine oxidases (MAO-A, MAO-B) metabolize biogenic 
amines and have been implicated in neuronal apoptosis. Al-
though apoptosis is an important process in embryo develop-
ment, the role of MAO isoenzymes has not been investigated in 
detail. We found that expression of MAO-A and MAO-B can be 
detected early on during embryo development. Expression lev-
els remained constant until around midgestation but then 
dropped to almost undetectable levels toward birth. Similar 
expression kinetics were observed in the brain. Isoform-specific 
expression silencing of MAO-A mediated by siRNA during in 
vitro embryogenesis induced developmental defects, as indi-
cated by a reduction of the crown rump length and impaired 
cerebral development. These alterations were paralleled by ele-
vated serotonin levels. Similar abnormalities were observed 
when embryos were cultured in the presence of the MAO-A 
inhibitor clorgyline or when the transcriptional inhibitor of 
MAO-A expression Rl was overexpressed. In contrast, no such 
alterations were detected when expression of MAO-B was 
knocked down. To explore the underlying mechanisms for the 
developmental abnormalities in MAO-A knockdown embryos, 
we quantified the degree of developmental apoptosis in the 
developing brain. MAO-A knockdown reduced the number of 
apoptotic cells in the neuroepithelium, which coincided with 
impaired activation of caspases 3 and 9. Moreover, we observed 
reduced cyclin Dl levels as an indicator of impaired cell prolif-
eration in MAO-A knockdown embryos. This data highlights 
MAO-A as a vital regulator of embryonic brain development. 
Monoamine oxidases (MAOs)2 are catalytically active flavo-
proteins that are widely expressed in the animal kingdom (1). 
They catalyze the oxidation of endogenous and xenobiotic 
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amines to the corresponding aldehydes. This reaction requires 
molecular dioxygen and produces stoichiometric amounts of 
hydrogen peroxide and ammonia (2). In higher animals, there 
are two M A O isoforms, referred to as M A O - A and M A O - B (3), 
which share a high degree (70%) of amino acid conservation. 
The two isozymes can be distinguished with respect to their 
substrate specificity and their sensitivity toward inhibitors (4). 
A major site of M A O expression is the CNS. In adult rats, 
M A O - A is predominantly found in catecholaminergic neurons, 
and highest concentrations are detected in the locus coerulus 
(5). In contrast, M A O - B is most abundant in serotonergic and 
histaminergic neurons as well as in glial cells (5). In the periph-
ery, distribution of M A O isoforms is variable, and there are 
species-specific differences (6). 
The two M A O isoforms are encoded for by separate genes on 
the X chromosome. The promoter regions of the genes have 
been investigated (7), and the transcriptional repressor R l was 
found to specifically bind and repress the M A O - A promoter 
(8). A functional promoter polymorphism of the M A O - A gene 
has been related to behavioral disorders (9). In humans, func-
tional inactivation of M A O genes is associated with a severe 
form of Norrie disease (10). In addition, pharmacologic inacti-
vation of M A O activity is a therapeutic approach for the treat-
ment of neurological disorders that have been shown to involve 
M A O activity, such as depression or neurodegenerative disor-
ders, including Parkinson's disease and Alzheimer's disease 
(11). 
To study the in vivo role of M A O isoenzymes in cerebral 
function, MAO-deficient mice have been employed. Targeted 
knockout of the M A O - B gene leads to viable offspring that 
show an altered stress response (12). Unfortunately, to date 
targeted inactivation of the M A O - A gene has not been carried 
out. However, naturally occurring MAO-A-deficient mice 
strains have been identified. Incidental insertion of an inter-
feron /3 minigene into exon 2 of the M A O - A gene abrogates the 
expression of a functional enzyme. These mice are viable and do 
not show obvious signs of functional defects in a resting state 
(13). However, they have significantly increased plasma levels 
of monoaminergic transmitters (serotonin, dopamine, norepi-
nephrine), are more susceptible to different kinds of stress, and 
exhibit a tendency for aggressive behavior (13). Similar obser-
vations were made in mice bearing a spontaneous point muta-
tion in exon 8, which introduced a premature stop codon anal-
ogous to a mutation found in humans suffering from Brunner 
28322 JOURNAL OF BIOLOGICAL CHEMISTRY ^ M P B I V . VOLUME 286- NUMBER 32-AUGUST 12,2011 
MAO-A Knockdown and Embryogenesis 
syndrome (14). A n identical mutation occurred in a colony of 
MAO-B-deficient mice, leading to M A O - A / B double knockout 
animals that are also viable but exhibit elevated monoamine 
levels and anxiety-like behavior (15). 
Monoamines are essential for proper cerebral function. 
Monoaminergic transmitter systems appear early on in 
embryogenesis (16), and serotonin, the biologically most rele-
vant M A O - A substrate, has been implicated in maturation of 
neuronal progenitors (17). MAO-A-deficient mice lack devel-
opmental clustering of layer IV granular neurons and suffer 
from aberrant maturation of the brainstem respiratory network 
(18, 19). Although the underlying mechanisms have not been 
studied in detail, these effects could be explained by the inabil-
ity of the animals to metabolize serotonin (20). This data is 
consistent with the recent observation that transgenic overex-
pression of M A O - A in the forebrain of M A O - A knockout mice 
rescues their aggressive behavior (21). 
Because the outcome of functional studies employing sys-
temic stem cell knockouts is frequently impacted by genetic 
drifts and epigenetic phenomena (22, 23), we employed the 
siRNA technology to explore the role of M A O isoforms in 
embryogenesis. This experimental setup allows us to study the 
impact of M A O expression at greater spatial and temporal 
specificity. For this purpose, we explanted murine embryos at 
early developmental stages, injected siRNA probes or specific 
inhibitors into the amniotic cavity, and cultured the treated 
embryos for up to 72 h in vitro (24). Using these genetic and 
pharmacological intervention strategies, we found that knock-
down of M A O - A expression disturbed embryonic brain devel-
opment and dysregulated developmental apoptosis. 
MATERIALS AND METHODS 
Chemicals—The chemicals used were from the following 
sources: Superscript III reverse transcriptase and RNaseOUT 
from Invitrogen, BD Advantage 2 polymerase mix from BD 
Biosciences, dNTPs from Carl Roth GmbH (Karlsruhe, Ger-
many), and PCR primers from BioTeZ Berlin-Buch GmbH 
(Berlin, Germany). 
RNA Extraction and Reverse Transcription—Total R N A was 
extracted using the RNeasy mini kit (Qiagen, Germany) and 
was reversely transcribed according to standard protocols with 
oligo d(T)15 primers and Superscript III reverse transcriptase 
(Invitrogen) according to the vendor's instructions. 
Quantitative RT-PCR—RT-qPCR was carried out with a 
RotorGene 3000 system (Corbett Research, Australia) using 
ImmoMix/SYBR Green (Bioline, Germany). Isoform-specific 
amplification primers were designed, and their sequences are 
given in supplemental Table SI. Absence of cross-amplification 
between the two isoforms was ensured, and the standard pro-
tocol has been described before (24). RNA preparations were 
analyzed at least in triplicate, and mean values are given. The 
experimental raw data were evaluated with the RotorGene 
Monitor software (version 4.6). To generate standard curves for 
quantification of expression levels, specific amplicons were 
used as external standards for each target gene (5 X 103 to 3 X 
106 copy numbers). G A P D H mRNA was used as the internal 
standard to normalize expression of the target transcripts. 
Preparation of Mouse Embryos and in Vitro Culture—All 
animal experiments were performed in strict adherence to the 
guidelines for experimentation with laboratory animals set in 
institutions. Inbred Institute for Cancer Research pregnant 
mice were obtained from the animal house, and embryos at 
different developmental stages (gestational day 6.5 (E6.5) to 
E17.5) were prepared under a stereomicroscope (Olympus). 
For RT-qPCR, preparations were kept in PBS (0.1% diethyl 
pyrocarbonate), and extraembryonic tissue was removed. For 
in vitro culture, the embryos were dissected in modified phos-
phate-buffered saline medium (5% FBS) as described before 
(24). 
Transfection Experiments—Tor our knockdown strategy, we 
designed isoform-specific siRNA using the Stealth™ RNAi 
program ( B L O C K - i T ™ RNAi Designer, Invitrogen). Among 
the designed probes we selected those constructs supplemental 
Table SI) exhibiting highest estimated knockdown probability 
and a GC content below 40%. No sequence cross-homology was 
allowed. Control siRNA duplexes with no homology to any 
vertebrate transcript were used as random control probes 
(Stealth™ RNAi negative controls, Invitrogen). For R l overex-
pression, the R l coding sequence was cloned into the mamma-
lian pcDNA3.1 expression vector supplemental Table SI). 
Empty vector was used as a control. For knockdown experi-
ments, murine embryos were explanted at E7.5 and transfected 
with siRNA constructs. 10 nl of annealed double-stranded 
siRNA (25-100 nil) were mixed with 0.01% Lipofectamine™ 
2000 (Invitrogen) and then microinjected with an Application 
Solution Transgenic platform micromanipulator (Leica, Ger-
many) into the amniotic cavity. After microinjection the 
embryos were placed in a whole embryo culture roller incuba-
tor (BTC Engineering, UK). The embryos at early gastrulation 
stage (E7.5) were allowed to develop for up to 72 h until early 
organogenesis stages E9.5-E10.5 in 100% heat-inactivated rat 
serum with a continuous flow of gas mixtures (24). 
Evaluation of Developmental Milestones—The impact of the 
treatments on embryonic growth (embryo size measured by the 
crown rump and head length) and on development of the brain, 
heart, and limbs was quantified by a microscopic scoring pro-
cedure. To judge cerebral embryogenesis, we assessed the 
degree of brain maturation by a number of morphological 
parameters (25). A score of 0 represented strong developmental 
retardations, whereas a score of 5 indicated normal develop-
ment. The following morphological criteria were applied for 
the different parts of embryonic brain: Forebrain: prosenceph-
alon invisible (score 0), V-shape (score 1), U-shape (score 2), 
partially fused (score 3), completely fused (score 4), telen-
cephalic evaginations (score 5). Midbrain: mesencephalic invis-
ible (score 0), V shape (score 1), U shape (score 2), partially 
fused (score 3), completely fused (score 4), discernible division 
between mesencephalon and diencephalons (score 5). Hind-
brain: rhombencephalon invisible (score 0), V shape (score 1), 
U shape (score 2), folds fused with anterior neuropore (score 3), 
anterior neuropore closure (score 4), dorsal flexion develops 
with 4th ventricle roof (score 5). Significances were calculated 
with Students' t test. 
MAO Activity Assays—Enzymatic activity of M A O isoforms 
was assayed in vitro with 14C-labeled tyramine hydrochloride as 
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a substrate, as described previously (26). The relative share con-
tributed by the two M A O isoforms was quantified using iso-
form-specific irreversible inhibitors. Clorgyline was used for 
specific inhibition of M A O - A and deprenyl for inhibition of 
M A O - B . 
In Situ Hybridization—In situ hybridization was performed 
according to Wilkinson's methods and as outlined previously 
(24). Suitable riboprobes (sense and antisense probes) were pre-
pared by PCR (supplemental Table SI), cloned, and transcribed 
using T7 RNA polymerase. To label the RNA probes, digoxige-
nin-11-UTP (Roche) was incorporated using the AmpliScribe 
T7 kit (Epicenter Technologies). Treated embryos and corre-
sponding controls were fixed in 4% p-formaldehyde, dehy-
drated in graded methanol solutions, and stored at — 20 °C prior 
to whole mount in situ hybridization. For section in situ hybrid-
ization, the fixed embryos were dehydrated in graded ethanol/ 
xylene mixtures and then embedded in paraffin (24). Sagittal 
sections (5 /im thick) of the embryos were prepared and stored 
at room temperature prior to in situ hybridization. 
Immunohistochemistry—lmmunohistochemical staining was 
performed on paraffin-embedded embryo sections employing the 
immunoperoxidase method. The antigenic epitopes were first 
exposed by heating the sections in 10 mM citrate buffer (pH 6.0) 
containing 0.05% Tween 20. After quenching the endogenous 
peroxidase with 3% hydrogen peroxide, sections were incu-
bated in TBS (5% normal sheep serum) containing either anti-
human M A O - A (clone C-19) or anti-human M A O - B (clone 
C-17) monoclonal antibodies (Santa Cruz Biotechnology, Inc.). 
The sections were then incubated with a peroxidase-labeled 
secondary antibody (Biocare Medical Kit), and slides were 
developed with diaminobenzidin (brown color). Negative con-
trols lacked the primary antibodies. 
Apoptotic cells were stained with both the supravital dye 
staining method and standard T U N E L technique. The whole 
mount supravital dye Nile blue sulfate visualizes non-viable 
cells. After cultivation, embryos at E10.5 were washed in Ring-
er's solution, bathed in a Nile blue sulfate solution for 15-20 
min at 37 °C, and then washed in Ringer's solution before 
microscopic examination. T U N E L staining was performed on 
embryo sagittal sections using the Chemicon kit according to 
the vendor's instructions. Nuclear D N A was counterstained 
with 0.5% (w/v) methyl green for microscopic examination. 
Western Blotting—Tor caspase 3, caspase 8, caspase 9, cyclin 
D l , E2F1, and /3-actin immunoblotting, whole embryo lysates 
were obtained by homogenizing embryos in lysis buffer (50 mM 
Tris HC1, 0.3 M NaCl, 1 mM EDTA, 1 mM DTT, and 1 mM 
PMSF). Aliquots with equal amounts of total protein (100 /xg) 
were separated on 12% SDS-PAGE gels, and separated proteins 
were transferred to nitrocellulose membranes (Amersham Bio-
sciences). The membranes were blocked overnight with an 
ovalbumin solution (Sigma) and then incubated at 37 °C for 1 h 
with primary antibodies. The membranes were then washed 
three times with TBS and incubated with HRP-labeled second-
ary antibody (Dako) at 1:1000 dilution (30 min at room temper-
ature). Blots were finally developed using the ECL kit (GE 
Healthcare). Immunoreactive protein bands were imaged using 
the Quantity One® quantification software (Bio-Rad) and nor-
malized to /3-actin expression. For M A O and R l immunoblot-
ting, primary antibodies were purchased from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA), but for quantification of 
caspase 3, caspase 8, caspase 9, and /3-actin, antibodies were 
obtained from Abeam, Inc. (Cambridge, UK). 
Serotonin Assay—Serotonin concentration in the embryos 
were measured using the Serotonin enzyme immunoassay (Ultra 
Sensitive) kit (Immuno Biological Laboratory, Inc.) according to 
the manufacturer's instructions. In brief, after treatments in vitro 
cultured embryos were washed and homogenized, and aliquots of 
the lysates were applied for quantification. The lower detection 
limit of the kit was 1.0 nmol/liter, and a linear calibration plot was 
established between 1.45 and 100 nmol/liter (r2 = 0.9807 ± 
0.0012). The intra- and interassay variation coefficients were < 
3.02%, and the recovery range varied between 100.4 and 102.3%. 
RESULTS 
Expression of MAO mRNA During the Time Course of Murine 
Embryogenesis—Previous in situ hybridization indicated that 
M A O isoforms are expressed in embryonic mouse brain as 
early as at E12 (17). Employing a more sensitive quantitative 
RT-PCR (RT-qPCR) strategy, we detected M A O mRNA spe-
cies much earlier on during mouse embryogenesis. At E6.5, 
M A O - A mRNA was clearly detectable, and its concentration 
increased until E9.5. Then it remained at constant levels until 
E13.5 (Fig. L4). At E14.5, M A O - A mRNA levels dropped and 
did not recover until birth. M A O - B mRNA follows similar 
expression kinetics, but its average steady state concentration 
was 4-fold lower than M A O - A mRNA. The prevalence of 
M A O - A over M A O - B in murine embryos was confirmed by 
activity assays (Fig. 15). More than 90% inhibition of total M A O 
activity was observed when total embryonic lysates were 
assayed in the presence of 10~7 M clorgyline, a specific M A O - A 
inhibitor. In contrast, when the MAO-B-specific inhibitor 
deprenyl was used, a similar degree of inhibition was only 
observed at 10~5 M . 
To follow cerebral expression of M A O isoforms during 
embryo development, we prepared embryonic brains at differ-
ent developmental stages and recorded the concentration pro-
files for M A O mRNAs (Fig. 1C). Cerebral M A O - A mRNA fol-
lows similar expression kinetics as in the whole embryo, with 
constant levels from E10.5 to E13.5, and dropped down to lower 
levels when the embryos approached birth. M A O - B mRNA 
concentrations are lower than those of M A O - A and decline 
further toward delivery. 
To explore the spatial distribution of M A O mRNA expres-
sion during embryogenesis, we performed in situ hybridization 
(Fig. 2). Between E10.5 and E12.5, specific signals for M A O - A 
mRNA expression (blue staining indicated by the red arrows) 
were mainly observed in developing brains. Low levels of in situ 
hybridization signals for M A O - B mRNA were detected in the 
fore- and hindbrain at E10.5. At later stages (Ell.5 and E12.5), 
the signals were even less intense. 
Silencing of MAO-A Expression Induced Developmental 
Defects—To silence expression of M A O - A and M A O - B during 
in vitro embryogenesis, we designed different specific siRNA 
probes for each MAO-isoform (supplemental Table SI). In an 
initial experiment, different siRNA species were injected into 
the amniotic cavity, and embryos were recovered after a cultur-
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FIGURE 1. Expression kinetics of MAO isoforms during mouse embryo 
development. A MAO expression in whole embryos. Mouse embryos (n = 5) 
were dissected at different developmental stages (E6.5 to El 7.5) and pooled 
together. Total RNA was extracted, and expression levels of MAO isoforms 
were quantified by RT-qPCR in triplicates (see "Materials and Methods"). 
6, MAO activity assay of whole embryos. Mouse embryos of gestation day 
El 3.5 were homogenized, and total enzymatic activity was assayed as 
described under "Material and Methods" using tyramine as a substrate. The 
relative shares of the two different MAO isoforms contributing to the total 
activity were quantified by adding isoform-specific inhibitors (clorgyline is 
MAO-A specific, deprenyl is MAO-B specific) at different concentrations. 
C, MAO expression in embryonic brain. Mouse embryos were removed at 
different developmental stages (El 0.5-E17.5), brains were isolated, and prep-
arations from five different individuals were pooled. Total RNA was extracted 
from these pools, and expression levels of MAO isoforms were quantified by 
RT-qPCR in triplicates (see "Materials and Methods"). The error bars mirror the 
accuracy of the assay system. The biological variability was averaged by pool-
ing the tissue of five different individuals. 
ing period of 72 h. Following knockdown of M A O - A using two 
independent siRNA constructs, we observed severe develop-
mental retardations for both siRNA species, as indicated by the 
reduced embryo size compared with embryos treated with 
scrambled siRNAs (Fig. 3A). In contrast, embryos treated with 
siRNAs targeted at M A O - B expression did not have an appar-
ent impact on embryo development (data not shown). 
To characterize the siRNA-induced developmental defects 
in different organ systems in more detail, we employed a mor-
phometric scoring system (25). This scoring system enabled us 
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FIGURE 2. In situ hybridization of embryonic brain sections at different 
developmental stages. In situ hybridization for MAO-A and MAO-B was per-
formed as outlined under "Material and Methods." Positive hybridization sig-
nals are indicated by the blue staining, and red arrows indicate brain regions 
with high MAO expression, fb, forebrain; hb, hindbrain. 
• control siRNA 
• MAO-A siRNA 
• MAO-B siRNA 
FIGURE 3. Knockdown of MAO-A expression using two independent 
siRNA constructs. For knockdown studies, MAO-A-specific siRNA constructs 
(siRNA-l and siRNA-ll) or corresponding controls were mixed with an appro-
priate volume of transfection reagent (see "Materials and Methods"). Murine 
embryos were explanted at E7.5, and the transfection mixture (10 nl with 50 
nM probe) was injected into the amniotic cavity. Embryos were then main-
tained in in vitro cultures for 72 h (El 0.5), and the silencing of MAO-A expres-
sion was assessed. A, macroscopy. The blue arrows indicate developmental 
defects of the brain. The figures are representative of five independent exper-
iments. 8, developmental scoring. After the culturing period, the crown-rump 
length and developmental defects in different organ system were evaluated 
by a numeric scoring procedure or in millimeters {mm) for crown-rump length 
(see "Materials and Methods"). Significances were calculated using Student's 
ftest.n = 10.*,p<0.01. 
to translate the developmental progress at organ and tissue lev-
els into a quantifiable matrix of scoring points. Using this sys-
tem, we evaluated the siRNA-induced developmental defects of 
the developing brain, heart, and limbs in addition to general 
growth retardations (crown rump length). We found that 
siRNA-mediated knockdown of M A O - A expression reduced 
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FIGURE 4. Impact of MAO expression silencing on embryo development. For knockdown studies, siRNA constructs or corresponding control probes were 
mixed with an appropriate volume of transfection reagent (see "Materials and Methods"). Murine embryos were explanted at E7.5, and the transfection mixture 
(10 nl with 50 nM probe) was injected into the amniotic cavity. The embryos were then maintained in in vitro cultures for 2 h (E7.5), 24 h (E8.5), 48 h (E9.5) and 
72 h (El 0.5), and silencing of MAO expression was tested. Whole mount in situ hybridization: Mouse embryos were removed from in vitro culture and in situ 
hybridization with MAO mRNA antisense probes was carried out. The red arrows indicate MAO mRNA expression. The blue arrows indicate developmental 
defects of the brain, fb, forebrain; mb, midbrain; hb, hindbrain; hf, headfold; tb, tail bud. 
the crown-rump length and significantly attenuated the devel-
opmental scores for the fore-, mid-, and hindbrain (Fig. 35). On 
the other hand, development of the heart and the limbs was not 
significantly altered. Although all siRNA-treated embryos at 
E10.5 exhibited normal neural tube closure, M A O - A knock-
down embryos showed retarded development (lower morpho-
metries scores), mainly because of delayed segmentation of the 
rhombomeres in the hindbrain and of the diencephalon in the 
midbrain. In contrast, knockdown of M A O - B expression did 
not induce developmental defects in any of the analyzed 
embryo parts within our experimental time window (Fig. 35). 
The success of the knockdown strategy was verified by whole 
mount in situ hybridization. Strong expression of both M A O 
isoforms was observed in the head region, as indicated by the 
dark blue in vitro hybridization signals (Fig. 4). Embryos treated 
with siRNA species targeted at M A O - A expression exhibited 
strongly reduced in situ hybridization signals after 72 h incuba-
tion (Fig. 4, panels 1-4). Similar results were observed when 
embryos were treated with M A O - B siRNA (Fig. 4, panels S- 8). 
These data suggest successful knockdown of the expression of 
either M A O isoform. 
Next, we aimed to analyze the effects of M A O knockdown at 
different time points during our experimental time frame. Both 
M A O isoforms are expressed at E7.5 and E8.5 in the headfold 
region and in the caudal neural tube, as indicated by the dark in 
situ hybridization signals (Fig. 4). At these developmental 
stages injection of siRNA constructs strongly reduced expres-
sion of the corresponding M A O isoform without causing 
apparent developmental alterations. At E9.5 mRNA of both 
M A O isoforms was mainly detected in the developing fore-, 
mid-, and hindbrain and the forelimbs. Faint in situ hybridiza-
tion signals found in the developing heart indicate expression of 
M A O - A in this organ (Fig. 4, red arrows). Treatment with spe-
cific siRNA selectively reduced M A O isoform expression. 
However, at this stage (Fig. 4, upper panel), we observed devel-
opmental defects as indicated by the reduced size of the whole 
embryo and of the developing brain (blue arrow). In conclusion, 
developmental retardations induced by M A O - A siRNA are 
apparent by day E9.5 but become most pronounced at day 
E10.5. 
To confirm siRNA-mediated knockdown of M A O isoforms 
on the protein level, we performed immunohistochemistry and 
Western blotting (Fig. 5, A and 5). Here we detected isoform-
specific and dose-dependent siRNA-induced reduction of 
M A O protein. This indicates successful down-regulation of 
target gene expression as well as a high isoform specificity 
of our siRNA constructs. 
To make sure that our knockdown data is not the results of 
methodological artifacts (off-target effects of the siRNA con-
structs) we employed two additional experimental approaches. 
Firstly, we used the specific and irreversible inhibitor of 
M A O - A activity clorgyline. Secondly, we transfected the devel-
oping embryos with a mammalian expression plasmid that 
drives the overexpression of the transcriptional inhibitor of 
M A O - A expression R l . Indeed, our Western blotting data indi-
cates specific suppression of M A O - A but not of M A O - B 
expression following R l overexpression (Fig. 5C). 
Reduced expression and/or activity of M A O - A has been 
reported to be associated with increased systemic levels of its 
substrate serotonin (13, 15). This prompted us to measure 
embryonic serotonin levels following M A O - A knockdown. 
Indeed, we observed that embryonic serotonin levels were ele-
vated almost 4-fold 72 h after M A O - A siRNA treatment (Fig. 
5D). Similarly, serotonin levels were also elevated when 
M A O - A activity was inhibited by clorgyline or when M A O - A 
gene transcription was suppressed by R l overexpression. 
Inhibition of MAO-A Activity Induces Developmental Defects 
Similar to MAO-A Knockdown—If the developmental abnor-
malities observed following siRNA-mediated knockdown of 
M A O - A expression are specific, pharmacological inhibition of 
M A O - A activity or suppression of M A O - A gene expression by 
R l overexpression should induce similar developmental alter-
ations as siRNA treatment. Indeed, when embryos were cul-
tured in the presence of clorgyline or when R l was overex-
pressed, embryo growth was impaired to a similar extent as 
observed for M A O - A knockdown embryos (Fig. 6, A and C). 
Clorgyline treatment resulted in retarded development of the 
hind- and midbrain, whereas development of the forebrain was 
less affected (Fig. 65). Development of the limbs and the heart 
proceeded normally. Similar observations were made when R l 
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was overexpressed (Fig. 6D). Thus, embryos treated with clor-
gyline or in whom R l was overexpressed phenotypically resem-
ble M A O - A knockdown embryos. 
Knockdown of MAO-A Expression Inhibited Developmental 
Apoptosis—Apoptosis is a vital process in embryo development 
(27) and M A O - A has been implicated in the regulation of cell 
proliferation and programmed cell death (26, 28). To test 
whether knockdown of M A O - A expression impacts develop-
mental apoptosis during murine embryogenesis, we first mon-
itored embryonic cell death by whole mount Nile blue staining 
of embryos at E10.5 (30-somite stage) and by the T U N E L tech-
nique in microscopic cross-sections (Fig. 7A). When we 
knocked down embryonic expression of M A O - A , the number 
of dead (Nile blue staining) and apoptotic cells (TUNEL stain-
ing) in the neuroepithelium of the developing brain was 
decreased significantly (yellow and red arrows, respectively) 
(Fig. 7A). 
For more detailed information on the mechanisms of the 
developmental defects, we repeated the knockdown experi-
ments and evaluated the impact of the siRNA constructs on the 
activation state of various caspases (Fig. 7, B and C). M A O - A is 
thought to modulate the intrinsic branch of the apoptotic path-
way involving caspase 3 and caspase 9 (26). When we knocked 
down embryonic M A O - A expression, the activation states of 
caspase 3 and caspase 9 were reduced significantly, whereas 
activation of caspase 8 was not altered (Fig. 7, B and C). These 
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data suggest that knockdown of M A O - A expression reduces 
apoptotic cell death by interfering with the intrinsic pathway of 
apoptosis. 
Neural development relies on the fine balance between apo-
ptotic cell death on one hand and cell proliferation and differ-
entiation on the other (29). M A O - A has been shown to modu-
late cell proliferation by regulating intracellular levels of cyclin 
D l and E2F1 (28). Cyclin D l specifically associates with 
selected cyclin-dependent kinases, phosphorylating the retino-
blastoma protein 1 (Rbl). This phosphorylation suppresses the 
growth inhibitory activity of hypophosphorylated Rbl and thus 
induces cell proliferation by releasing E2F1 (30). We found that 
M A O - A knockdown was paralleled by a reduction in cellular 
cyclin D l levels (Fig. 75). In contrast, cellular levels of the tran-
scriptional regulator E2F1 whose activity is associated with pro-
liferation (31) remained unaffected by any treatment (Fig. 75). 
Similar observations were made when M A O - A activity was 
inhibited using clorgyline or when M A O - A expression was sup-
pressed by R l overexpression. 
DISCUSSION 
In vertebrates M A O isoforms metabolize neurotransmitters 
and thus are important for the functionality of the adult brain. 
However, the role of M A O in murine embryonic development 
is less well understood. To fill this gap of knowledge, we em-
ployed an in vitro embryogenesis model (24). Mouse strains 
that exhibit incidental inactivation of the M A O - A gene are fer-
tile and only show minor developmental alterations (13, 14), 
which appears to conflict with the robust changes we observed. 
However, our experimental setup avoids limitations of stem 
cell-based approaches, such as adaptive or compensational 
effects (23). Such effects may be responsible for the lack of 
developmental defects in MAO-A-deficient mouse strains (13, 
14). Moreover, our experimental approach causes a sudden 
reduction of M A O - A expression at a certain developmental 
stage in embryos that have grown in the presence of M A O - A 
until expression knockdown was initiated. Knockout embryos, 
in contrast, might have activated compensatory mechanisms 
during early embryo development that are not available any-
more at later developmental stages. In this respect, the two 
experimental models (knockout versus knockdown) are differ-
ent and may lead to different experimental data. To make sure 
that our knockdown data are not the result of methodological 
artifacts, we combined genetic (siRNA-mediated M A O - A 
knockdown and R l overexpression) and pharmacological 
(MAO-A inhibitor clorgyline) approaches and obtained identi-
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cal results. In fact, recent observations of impaired cell prolif-
eration of the telencephalon during late embryo development 
in an MAO-A/B-deficient mouse line supports our line of argu-
mentation that M A O - A affects prenatal development (32). 
Our studies indicate that both M A O - A and M A O - B are 
expressed at early stages when neuronal differentiation (gastru-
lation and neurulation) is induced and major subdivision of the 
brain (migration, specification, segmentation) takes place (33). 
M A O - A is a proapoptotic enzyme, and caspase 3 and caspase 9 
of the intrinsic pathway of apoptosis have been related to 
M A O - A activity (26, 34). Moreover, M A O - A appears to mod-
ulate cell proliferation via controlling cytoplasmic cyclin D l 
and E2F1 levels (28). The precise mechanisms of MAO-medi-
ated regulation of cellular signaling cascades have not been 
explored in detail. A potential effector molecule is hydrogen 
peroxide, which is generated by M A O activity and affects both 
mitochondrial function and the cellular redox state (35,36). On 
one hand, mitochondrial dysfunction is a feature of the intrinsic 
pathway of cell death signaling and is paralleled by increased 
lipid peroxidation of the mitochondrial membranes (37). On 
the other hand, changes of the cellular redox state affect a mul-
titude of signaling cascades involved in the regulation of cellular 
proliferation and differentiation (38). However, more research 
is needed to understand the role of M A O - A derived hydrogen 
peroxide in the regulation of these signaling events. 
Moreover, M A O - A has been implicated in cell cycle progres-
sion mediated by the oncogene c-myc (28). The myc protein 
acts as a transcription factor that modulates the expression of a 
variety of genes associated with cell cycle regulation, including 
E2F1 and cyclin D l (39-41). In addition, c-myc regulates the 
expression as well as the activity of the transcription factor R l 
(28). We observed similar developmental abnormalities in 
embryos overexpressing R l compared with M A O - A knock-
down embryos. Moreover, R l overexpression similar to 
M A O - A knockdown or pharmacological inhibition of M A O - A 
activity coincides with elevated levels of the cyclin D l protein. 
In conclusion, this data implicates M A O - A as an integral medi-
ator of the c-myc proliferation signaling cascade via modulating 
cyclin D l levels. 
Developmental apoptosis is a well balanced process that is 
crucial for the formation of embryonic structures. Disturbance 
of this equilibrium induces morphological abnormalities, such 
as neural tube defects (29, 42). We found that M A O - A knock-
down embryos and embryos exposed to clorgyline showed nor-
mal neural tube closure, which was followed by decreased apo-
ptosis as well as impaired cell proliferation. Embryos of caspase 
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3-deficient mice die before birth and exhibit profoundly 
impaired brain development and cellular hyperplasia (43). In 
our M A O - A knockdown studies, caspase 3 activation was sig-
nificantly impaired, which is in line with caspase 3 knockout 
data. 
A hallmark of M A O - A deficiency in previously reported ani-
mal models are elevated levels of serotonin (13). We also 
observed elevated embryonic serotonin levels following 
M A O - A knockdown or following pharmacologic inhibition of 
M A O - A activity. These data underline the validity of the differ-
ent experimental setups. Elevated 5-HT levels were also found 
in neural stem cells treated with Moclobemide, a reversible 
inhibitor of M A O - A activity. M A O - A inhibition resulted in an 
induction of the expression of the anti-apoptotic factor Bcl-2 in 
neural stem cells via ERK activation, and thereby inhibited 
apoptotic signaling and subsequently induced stem cell differ-
entiation (34). Newborn mice lacking the cerebral vesicular 
monoamine transporter (VMAT2~ / ~) suffer from increased 
developmental apoptosis in the cerebral cortex (44). In these 
animals, caspase 3 and caspase 9 are hyperactive, and expres-
sion of antiapoptotic Bcl-XL was reduced. When these mice 
were crossed with M A O - A deficient animals ( V M A T 2 ~ / ~ / 
M A O - A _ / ~ double K O mice), 5-HT levels were elevated, and 
the increased cell death induced by V M A T 2 deficiency was 
normalized (44). This finding is consistent with our data and 
also implicates M A O - A in proper brain development. 
Although our data suggest M A O - A as an important player in 
the regulation of cerebral embryogenesis, more work is needed 
to identify the components of the associated signaling cascades. 
For instance, dysregulation of the finely tuned spatial and tem-
poral balance between 5-HT production and breakdown may 
have fatal consequences for the developing embryo. Indeed, for 
several years it has been a matter of discussion of whether or not 
pharmacological intervention aimed at 5-HT homeostasis, 
such as selective serotonin reuptake inhibitors, during preg-
nancy has teratogenic effects (45,46). 
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